which specializes in vaccines and antibody therapies. Crucell's board of directors unanimously supports the deal, and shareholders will vote on the matter on 8 february.
Small proteins, antibodies, and viruses were amenable to the technology and within reach of a startup.
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011